The antiviral treatment of chronic hepatitis B is limited by the selection of antiviral resistance mutations. Primary resistance to lamivudine occurs at rtM204I/V in the C Domain of the polymerase. Recently, resistance to adefovir has also been described in the D Domain at rtN236T. The treatment of patients with resistant virus without complete suppression can lead to the further selection of compensatory mutations. Thus, to gain an understanding of the hepatitis B virus (HBV) polymerase and also mutations associated with resistance, a three-dimensional model of the HBV reverse transcriptase core region based on homology with human immunodeficiency virus (HIV) was created. A comparative analysis of the HIV polymerase and the model of HBV polymerase was performed. In addition, the antiviral resistance mutations including potential compensatory mutations were mapped to determine their effect on the HBV polymerase model, especially in the nucleotide binding site.
References
1.
PochO., SauvagetI., DelarueM., & TordoN.Identification of four conserved motifs among the RNA-dependent polymerase encoding elements.EMBO Journal1989; 8: 3867–3874.
2.
LesburgC.A., CableM.B., FerrariE., HongZ., MannarinoA.F., & WeberP.C.Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site.Nature Structural Biology1999; 6(10): 937–943.
3.
NakamuraT.M., MorinG.B., ChapmanK.B., WeinrichS.L., AndrewsW.H., LingnerJ., HarleyC.B., & CechT.R.Telomerase catalytic subunit homologs from fission yeast and human.Science1997; 277: 955–959.
4.
XiongY., & EickbushT.H.Origin and evolution of retroelements based upon their reverse transcriptase sequences.EMBO Journal1990; 9(10): 3353–3362.
5.
StuyverL.J., LocarniniS.A., LokA., RichmanD.D., CarmanW.F., DienstagJ.L., & SchinaziR. F.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.Hepatology2001; 33(3): 751–757.
6.
SawayaM.R., PelletierH., KumarA., WilsonS.H., & KrautJ.Crystal structure of rat DNA polymerase beta: evidence for a common polymerase mechanism.Science1994; 264(5167): 1930–1935.
7.
BartholomeuszA., SchinaziR., & LocarniniS.Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease.Viral Hepatitis Reviews1998; 4: 167–187.
8.
AllenM.I., DeslauriersM., AndrewsC. W., TipplesG.A., WaltersK.A., TyrrellD.L., BrownN., & CondreayL.D.Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Hepatology1998; 27(6): 1670–1677.
9.
DasK., XiongX., YangH., WestlandC.E., GibbsC.S., SarafianosS.G., & ArnoldE.Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).Journal of Virology2001; 75(10): 4771–4779.
10.
SaliA., & OveringtonJ.Derivation of rules for comparative protein modelling from a database of protein structure alignments.Protein Science1994; 3: 1582–1596.
11.
HuangH., ChopraR., VerdineG.L., & HarrisonS.C.Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance [see comments].Science1998; 282(5394): 1669–1675.
12.
RodgersD.W., GamblinS.J., HarrisB.A., RayS., CulpJ.S., HellmigB., WoolfD.J., DebouckC., & HarrisonS.C.The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.Proceedings of the National Academy of Sciences, USA1995; 92(4): 1222–1226.
13.
WrobelJ.A., ChaoS.F., ConradM.J., MerkerJ.D., SwanstromR., PielakG.J., & HutchisonC.A.3rd. A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase.Proceedings of the National Academy of Sciences, USA1998; 95(2): 638–645.
14.
DelaneyW.E.4th, EdwardsR., ColledgeD., ShawT., TorresiJ., MillerT.G., IsomH.C., BockC.T., MannsM.P., TrautweinC., & LocarniniS.Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.Antimicrobial Agents & Chemotherapy2001; 45(6): 1705–1713.
15.
LaiC.L., ChienR.N., LeungN.W., ChangT.T., GuanR., TaiD.I., NgK.Y., WuP.C., DentJ.C., BarberJ., StephensonS.L., & GrayD.F.A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.New England Journal of Medicine1998; 339(2): 61–68.
16.
LeungN.Treatment of chronic hepatitis B: case selection and duration of therapy.Journal of Gastroenterology & Hepatology2002; 17(4): 409–414.
17.
WintersM.A., CoolleyK.L., ChengP., GirardY.A., HamdanH., KovariL.C., & MeriganT.C.Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.Journal of Virology2000; 74(22): 10707–10713.
18.
SawayaM.R., PrasadR., WilsonS.H., KrautJ., & PelletierH.Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism.Biochemistry1997; 36(37): 11205–11215.
19.
WhiteK.L., MargotN.A., WrinT., PetropoulosC.J., MillerM.D., & NaegerL.K.Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.Antimicrobial Agents & Chemotherapy2002; 46(11): 3437–3446.
20.
ChisariF., & FerrariC.Hepatitis B virus immunopathogenesis.Annual Review of Immunology1995; 13: 29–60.
21.
SeigneresB., PichoudC., AhmedS.S., HantzO., TrepoC., & ZoulimF.Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.Journal of Infectious Diseases2000; 181(4): 1221–1233.
22.
BoyerP.L., LisziewiczJ., LoriF., & HughesS.H.Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase.Journal of Molecular Biology1999; 286(4): 995–1008.
23.
TantilloC., DingJ., Jacobo-MolinaA., NanniR.G., BoyerP.L., HughesS.H., PauwelsR., AndriesK., JanssenP.A., & ArnoldE.Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.Journal of Molecular Biology1994; 243(3): 369–387.
24.
GuZ., GaoQ., LiX., ParniakM.A., & WainbergM.A.Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine.Journal of Virology1992; 66(12): 7128–7135.
25.
LarderB.A., DarbyG., & RichmanD.D.HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.Science1989; 243(4899): 731–734.
26.
LarderB.A., BloorS., KempS.D., HertogsK., DesmetR.L., MillerV., SturmerM., StaszewskiS., RenJ., StammersD.K., StuartD.I., & PauwelsR.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.Antimicrobial Agents & Chemotherapy1999; 43(8): 1961–1967.
27.
ShahF.S., CurrK.A., HamburghM.E., ParniakM., MitsuyaH., ArnezJ.G., & PrasadV.R.Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase.Journal of Biological Chemistry2000; 275(35): 27037–27044.
28.
RenJ., EsnoufR.M., HopkinsA.L., JonesE.Y., KirbyI., KeelingJ., RossC.K., LarderB.A., StuartD.I., & StammersD.K.3′-Azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.Proceedings of the National Academy of Sciences, USA1998; 95(16): 9518–9523.
29.
MulatoA.S., LamyP.D., MillerM.D., LiW.X., AntonK.E., HellmannN.S., & CherringtonJ.M.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Antimicrobial Agents & Chemotherapy1998; 42(7): 1620–1628.
30.
GuZ., SalomonH., CherringtonJ.M., MulatoA.S., ChenM.S., YarchoanR., FoliA., SogocioK.M., & WainbergM.A.K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.Antimicrobial Agents & Chemotherapy1995; 39(8): 1888–1891.
31.
BoyerP.L., SarafianosS.G., ArnoldE., & HughesS.H.Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.Proceedings of the National Academy of Sciences, USA2000; 97(7): 3056–3061.
32.
OgataN., FujiiK., TakigawaS., NomotoM., IchidaT., & AsakuraH.Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B.Journal of Medical Virology1999; 59(3): 270–276.
33.
BockC.T., TillmannH.L., TorresiJ., KlempnauerJ., LocarniniS., MannsM.P., & TrautweinC.Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.Gastroenterology2002; 122(2): 264–273.
34.
TillmannH.L., TrautweinC., BockT., BokerK.H., JackelE., GlowienkaM., OldhaferK., BrunsI., GauthierJ., CondreayL.D., RaabH.R., & MannsM.P.Mutational analysis of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.Hepatology1999; 30: 244–256.
35.
TorresiJ., Earnest-SilveiraL., DeliyannisG., EdgttonK., ZhuangH., LocarniniS.A., FyfeJ., SozziT., & JacksonD.C.Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.Virology2002; 293(2): 305–313.
36.
KaushikN., TaleleT.T., PandeyP.K., HarrisD., YadavP.N., & PandeyV.N.Role of glutamine 151 of human immunodeficiency virus type-1 reverse transcriptase in substrate selection as assessed by site-directed mutagenesis.Biochemistry2000; 39(11): 2912–2920.
37.
XiongX., FloresC., YangH., TooleJ.J., & GibbsC.S.Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.Hepatology1998; 28: 1669–1673.
38.
XiongX., YangH., WestlandC.E., ZouR., & GibbsC.S.In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.Hepatology2000; 31: 219–224.
39.
YehC.T., ChienR.N., ChuC.M., & LiawY.F.Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.Hepatology2000; 31(6): 1318–1326.
40.
BallesterosJ.A., DeupiX., OlivellaM., HaaksmaE.E., & PardoL.Serine and threonine residues bend alpha-helices in the chi(1) = g(-) conformation.Biophysical Journal2000; 79(5): 2754–2760.
MellorsJ.W., BazmiH.Z., SchinaziR.F., RoyB.M., HsiouY., ArnoldE., WeirJ., & MayersD.L.Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.Antimicrobial Agents & Chemotherapy1995; 39(5): 1087–1092.
43.
UenoT., ShirasakaT., & MitsuyaH.Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates.Journal of Biological Chemistry1995; 270(40): 23605–23611.
44.
ShirasakaT., KavlickM.F., UenoT., GaoW.Y., KojimaE., AlcaideM.L., ChokekijchaiS., RoyB.M., ArnoldE., & YarchoanR.Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.Proceedings of the National Academy of Sciences, USA1995; 92(6): 2398–2402.
45.
KosalaraksaP., KavlickM.F., MarounV., LeR., & MitsuyaH.Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay.Journal of Virology1999; 73(7): 5356–5363.
46.
MelegariM., Scaglioni, & WandsJ.Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.Hepatology, 1998; 27(2): 628–633.
47.
RadziwillG., TuckerW., & SchallerH.Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity.Journal of Virology1990; 64: 613–620.
48.
KohlstaedtL.A., WangJ., FriedmanJ.M., RiceP.A., & SteitzT.A.Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.Science1992; 256(5065): 1783–1790.
49.
Jacobo-MolinaA., DingJ., NanniR.G., ClarkA.D.Jr., LuX., TantilloC., WilliamsR.L., KamerG., FerrisA.L., & ClarkP.Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.Proceedings of the National Academy of Sciences, USA1993; 90: 6320–6324.
50.
NanniR.. Review of HIV-1 reverse transcriptase three dimensional structure: Implications for drug design.Perspectives Drug Discovery Design1993; 1: 129–150.
51.
LarderB.A., PurifoyD.J., PowellK.L., & DarbyG.Site-specific mutagenesis of AIDS virus reverse transcriptase.Nature1987; 327(6124): 716–717.
52.
BakhanashviliM., AvidanO., & HiziA.Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: the involvement of residues 183 and 184 in the fidelity of DNA synthesis.FEBS Letters1996; 391(3): 257–262.
53.
SchinaziR.F., LarderB.A., & MellorsJ.W.Mutations in retro-viral genes associated with drug resistance: 1999–2000 update.International Antiviral News1999; 7(4): 46–69.
54.
SarafianosS.G., DasK., ClarkA.D.Jr., DingJ., BoyerP.L., HughesS.H., & ArnoldE.Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.Proceedings of the National Academy of Sciences, USA1999; 96(18): 10027–10032.
55.
AvidanO., & HiziA.The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase.Nucleic Acids Research1998; 26(7): 1713–1756.
56.
GotteM., ArionD., ParniakM.A., & WainbergM.A.The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.Journal of Virology2000; 74(8): 3579–3585.
57.
PichoudC., SeigneresB., WangZ., TrepoC., & ZoulimF.Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.Hepatology1999; 29(1): 230–237.
58.
BartholomeuszA., & LocarniniS.Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine.International Antiviral News1997; 5: 123–124.
59.
HookerD.J., TachedjianG., SolomonA.E., GurusingheA.D., LandS., BirchC., AndersonJ.L., RoyB.M., ArnoldE., & DeaconN.J.An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine.Journal of Virology1996; 70(11): 8010–8018.
60.
HarriganP.R., KinghornI., BloorS., KempS.D., NajeraI., KohliA., & LarderB.A.Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.Journal of Virology1996; 70(9): 5930–5934.
61.
ShaferR.W., IversenA.K., WintersM.A., AguinigaE., KatzensteinD.A., & MeriganT.C.Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.Journal of Infectious Diseases1995; 172(1): 70–78.
62.
TachedjianG., AronsonH.E., & GoffS.P.Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.Proceedings of the National Academy of Sciences, USA2000; 97(12): 6334–6339.
